| abstract |
The modified release formulation (5) comprises a plurality of minicapsules or minispheres (1, 2) containing nimodipine and a plurality of minicapsules or minispheres (3), (4) containing tacrolimus. There are uncoated minicapsules or minispheres with micronized nimodipine for immediate release (1) and micronized nimodipine encapsulated controlled release polymer coated minicapsules or minispheres (2) for delayed, sustained, controlled or targeted release. Uncoated seamless mini capsule (3) with tacrolimus lipid based formulation for immediate release core and controlled release polymer coated seamless mini with core containing tacrolimus lipid based formulation for delayed, sustained, controlled release or targeted release There are capsules (4). The final dosage form can be a hard gelatin capsule (5). |